BIOMAT Database Logo BIOMAT Database Logo

[Systemic enzyme therapy in chronic glomerulonephritis]. 2000

O V Siniachenko, and V N Kovalenko, and I V Mukhin, and G A Ignatenko, and A I Terzov

OBJECTIVE To try polyenzyme drug vobenzim in chronic glomerulonephritis (CGN). METHODS 174 CGN patients were randomized into 2 groups. The study group of 39 patients received conventional pathogenetic treatment plus vobenzim (initial dose 18-24, maintenance 12-15 dragees a day). Control group of 135 patients were given only pathogenetic therapy. 67 patients appeared ineligible. RESULTS 3-6 months after the treatment the response was seen in 61.5% patients of the study and 17.8% patients of the control group. Side effects of vobenzim in CGN treatment were absent. CONCLUSIONS Enzyme therapy with vobenzim in CGN is safe and effective.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010447 Peptide Hydrolases Hydrolases that specifically cleave the peptide bonds found in PROTEINS and PEPTIDES. Examples of sub-subclasses for this group include EXOPEPTIDASES and ENDOPEPTIDASES. Peptidase,Peptidases,Peptide Hydrolase,Protease,Proteases,Proteinase,Proteinases,Proteolytic Enzyme,Proteolytic Enzymes,Esteroproteases,Enzyme, Proteolytic,Hydrolase, Peptide
D002908 Chronic Disease Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2). Chronic Condition,Chronic Illness,Chronically Ill,Chronic Conditions,Chronic Diseases,Chronic Illnesses,Condition, Chronic,Disease, Chronic,Illness, Chronic
D005260 Female Females
D005921 Glomerulonephritis Inflammation of the renal glomeruli (KIDNEY GLOMERULUS) that can be classified by the type of glomerular injuries including antibody deposition, complement activation, cellular proliferation, and glomerulosclerosis. These structural and functional abnormalities usually lead to HEMATURIA; PROTEINURIA; HYPERTENSION; and RENAL INSUFFICIENCY. Bright Disease,Kidney Scarring,Glomerulonephritides,Scarring, Kidney
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

O V Siniachenko, and V N Kovalenko, and I V Mukhin, and G A Ignatenko, and A I Terzov
[Systemic enzyme therapy of experimental gout glomerulonephritis].
January 2004, Patologicheskaia fiziologiia i eksperimental'naia terapiia,
O V Siniachenko, and V N Kovalenko, and I V Mukhin, and G A Ignatenko, and A I Terzov
[Urinary fibrinolytic enzyme activity in systemic diseases and chronic glomerulonephritis].
February 1988, Vrachebnoe delo,
O V Siniachenko, and V N Kovalenko, and I V Mukhin, and G A Ignatenko, and A I Terzov
[Experimental systemic enzyme therapy of gouty and primary glomerulonephritis].
January 2003, Eksperimental'naia i klinicheskaia farmakologiia,
O V Siniachenko, and V N Kovalenko, and I V Mukhin, and G A Ignatenko, and A I Terzov
[Treatment of dyslipoproteinemia by systemic enzyme therapy in experimental glomerulonephritis].
January 2002, Patologicheskaia fiziologiia i eksperimental'naia terapiia,
O V Siniachenko, and V N Kovalenko, and I V Mukhin, and G A Ignatenko, and A I Terzov
[Therapy of chronic glomerulonephritis].
February 1970, Monatsschrift fur Kinderheilkunde,
O V Siniachenko, and V N Kovalenko, and I V Mukhin, and G A Ignatenko, and A I Terzov
[Therapy of chronic glomerulonephritis].
November 1985, Kinderarztliche Praxis,
O V Siniachenko, and V N Kovalenko, and I V Mukhin, and G A Ignatenko, and A I Terzov
[Systemic enzyme therapy].
March 1996, Ceska a Slovenska farmacie : casopis Ceske farmaceuticke spolecnosti a Slovenske farmaceuticke spolecnosti,
O V Siniachenko, and V N Kovalenko, and I V Mukhin, and G A Ignatenko, and A I Terzov
Targeted enzyme therapy of experimental glomerulonephritis in rats.
May 1991, The Journal of clinical investigation,
O V Siniachenko, and V N Kovalenko, and I V Mukhin, and G A Ignatenko, and A I Terzov
[Therapy of primary chronic glomerulonephritis].
December 1994, Therapeutische Umschau. Revue therapeutique,
O V Siniachenko, and V N Kovalenko, and I V Mukhin, and G A Ignatenko, and A I Terzov
Cyclosporine therapy for chronic glomerulonephritis.
May 1986, Clinical nephrology,
Copied contents to your clipboard!